Adding Opdivo (nivolumab) to standard first-line chemotherapy significantly extends overall survival and delays disease progression or death in adults with inoperable advanced HER2-negative stomach cancer, esophageal adenocarcinoma, or gastroesophageal junction (GEJ) cancer, compared with chemotherapy alone, according to interim data from the CheckMate-649 Phase 3 trial. Notably, survival benefits were seen across several patient groups, regardless of the PD-L1 levels — the amount of the PDL1 protein on cancer cells — in their tumors. Bristol Myers Squibb’s…
You must be logged in to read/download the full post.
The post Opdivo Combo Found to Extend Survival in Advanced Stomach, Esophageal Cancers appeared first on BioNewsFeeds.